No association between HPV vaccination and risky sexual behaviors found in girls
the ONA take:
A significant concern in regard to young girls receiving the human papillomavirus (HPV) vaccine was that introducing the idea of sexual activity at a young age would increase the risk of those girls’ engaging in risky sexual behaviors.
Researchers at Harvard Medical School and the University of Southern California investigated the concept. Their findings suggest that the vaccine does not promote risky sexual behaviors among those who received it. The study included 21,000 girls who received the vaccination matched with 186,000 girls who did not receive it.
Both groups were the same age, had the same insurance plan, and lived in the same geographic area of the United States. The researchers measured rates of sexually transmitted infections (STIs) quarterly for 1 year before and 1 year after vaccination.
Although rates of STIs was slightly higher among the vaccinated girls before and after vaccination, the rate of STIs increased at the same pace in both groups. The researchers conclude that if receipt of the HPV vaccine caused an increase in risky sexual behavior, they would have seen a steeper increase in STIs among the vaccinated girls.
This did not occur, which lead to their conclusion that receipt of the HPV vaccine was not associated with unsafe sexual practices. Two HPV vaccines are currently available, Ceravix and Gardasil.
Both prevent cervical cancer; Gardasil also protects against genital warts and anal cancer in both girls and boys, and against vulvar cancer and vaginal cancer in girls. HPV vaccination is recommended for preteen girls and boys at age 11 or 12 years.
Gardasil protects against genital warts and anal cancer in both girls and boys, and against vulvar cancer and vaginal cancer in girls.
Sign Up for Free e-newsletters
- Triplet Regimen Found Most Effective for Relapsed/Refractory Multiple Myeloma
- Integrating Preoperative Oral Care Into Cancer Treatment Plans
- Current Status and Dilemma of Second-line Treatment in Advanced Pancreatic Cancer: Is There a Silver Lining?
- American Association for Cancer Research Releases Its 2018 Annual Report
- Pulmonary Toxicity Increased in Pediatric Hodgkin Lymphoma Treated With Brentuximab Vedotin
- Benefit of Chemotherapy for Breast Cancer Observed With Midrange Gene Assay Score
- Antioxidant Interaction With Cancer Therapy
- Young Survivors of Breast Cancer Report Sexual Quality of Life Declines After Treatment
- Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT
- Insurance Status Influences Overall Survival in Follicular Lymphoma
- Endocrine Society Released Guidelines for Managing Endocrine Disorders in Childhood Cancer Survivors
- Skin Cancer Screening: Are They Effective?
- Metronidazole, Vancomycin Recommended for C Difficile in Pediatric Oncology, HSCT
- CDC: HPV Vaccination Rates on the Rise Among Adolescents
- High-Dose vs Standard-Dose Flu Vaccine in Elderly Receiving Chemotherapy
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|